Form 4: Immunovant Executive Christopher Van Tuyl Reports Stock and Option Awards

Christopher Van Tuyl, Chief Legal Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On April 1, 2025, Christopher Van Tuyl, the Chief Legal Officer of Immunovant, Inc., was granted 50,787 restricted stock units (RSUs) and options to purchase 71,531 shares of common stock.
• The RSUs vest as to 25% on April 1, 2026, and the remainder vest in equal quarterly installments over three years, contingent upon continuous service.
• The stock options also vest as to 25% on April 1, 2026, with the remainder vesting in 36 equal monthly installments over three years, subject to continuous service.
• Van Tuyl also disposed of 160,743 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

This filing is a routine disclosure related to executive compensation and equity awards, common in the biotechnology industry to incentivize and retain key personnel.

Stakeholder Impact

• The equity grants align management's interests with those of shareholders, incentivizing long-term value creation.

Key Dates

Keywords

Immunovant, Van Tuyl, Stock Options, RSUs, Form 4, Beneficial Ownership, Equity Incentive Plan, Vesting